SCHEMBL5784476

SCHEMBL5784476

COc1cc2c(c3c1OC(C)(C)C3)C(c1cccc(O)c1)=NC(C)(C)C2

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.36
KDM4E B2RXH2 4/20 0.36
TP53 P04637 3/20 0.36
HPGD P15428 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 3/20 0.35
MAPT P10636 2/20 0.35
TSHR P16473 2/20 0.35
MITF O75030 1/20 0.35
KMT2A Q03164 1/20 0.35
SLC2A1 P11166 1/20 0.34
KDM1A O60341 1/20 0.33
MAOA P21397 1/20 0.33
PDE4D Q08499 1/20 0.33
NTSR1 P30989 1/20 0.33
GLA P06280 1/20 0.32
FFAR4 Q5NUL3 4/20 0.32
HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5787614 0.89 KDM4E (0.38) LMNAKDM4ETP53HPGDSMN1; SMN2
SCHEMBL5785621 0.89 TP53 (0.37) LMNAKDM4ETP53HPGDSMN1; SMN2
SCHEMBL5785757 0.88 KDM4E (0.41) LMNAKDM4ETP53HPGDSMN1; SMN2
SCHEMBL5783172 0.88 KDM4E (0.36) LMNAKDM4ETP53HPGDSMN1; SMN2
SCHEMBL5786854 0.88 MAPK10 (0.40) LMNAKDM4ETP53HPGDSMN1; SMN2
Hydrochloric Acid SCHEMBL5785611 0.88 KDM4E (0.36) LMNAKDM4ETP53HPGDSMN1; SMN2
Hydrochloric Acid SCHEMBL5783013 0.87 KDM4E (0.40) LMNAKDM4ETP53HPGDSMN1; SMN2
SCHEMBL5784191 0.87 KDM4E (0.35) LMNAKDM4ETP53HPGDSMN1; SMN2
Hydrochloric Acid SCHEMBL5785758 0.87 KDM4E (0.35) LMNAKDM4ETP53HPGDSMN1; SMN2
Hydrochloric Acid SCHEMBL5783296 0.87 MAPK10 (0.39) LMNAKDM4ETP53HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1270577-B1 FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2006-12-06 EP disclosed
US-20060106048-A1 Furoisoquinoline derivative and use thereof PASCALI, PETROS P. (CY) 2006-05-18 US disclosed
US-6924292-B2 Furoisoquinoline derivatives, process for producing the same and use thereof TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-02 US disclosed
EP-1541576-A1 FUROISOQUINOLINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed
US-20040092582-A1 Furoisoquinoline derivatives, process for producing the same and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 US disclosed
EP-1270577-A1 FUROISOQUINOLINE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092582-A1 Furoisoquinoline derivatives, process for producing the same and use thereof PDE3B, PDE5A, PDE3A LMNA 4533/4885KDM4E 300/4885TP53 3833/4885
US-20060106048-A1 Furoisoquinoline derivative and use thereof PDE3B, PDE2A, PDE3A LMNA 2455/4885KDM4E 358/4885TP53 4360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.